Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
351. |
ECCT/20/01/01 | LEVERAGING THE DEPRESSION AND PRIMARY-CARE PARTNERSHIP FOR EFFECTIVENESS-IMPLEMENTATION RESEARCH A SEQUENTIAL, MULTIPLE ASSIGNMENT RANDOMIZED TRIAL (SMART) FOR NON-SPECIALIST TREATMENT OF COMMON MENTAL DISORDERS IN KENYA: LEVERAGING THE DEPRESSION AND PRIMARY-CARE PARTNERSHIP FOR EFFECTIVENESS-IMPLEMENTATION RESEARCH (DAPPER) PROJECT (SMART-DAPPER) |
Principal Investigator(s) 1. Anne Muthoni Mathai 2. Susan Meffert Site(s) in Kenya Kisumu County Hospital |
31-03-2020 |
View |
352. |
ECCT/19/12/02 | VPM1002 Phase III PoI A multicenter, Phase III double blind, randomized active controlled study to evaluate efficacy and safety of VPM1002 in comparison with BCG in prevention of Mycobacterium tuberculosis infection in newborn infants. |
Principal Investigator(s) 1. Videlis Nduba Site(s) in Kenya 1. KEMRI-CRDR Nairobi (Nairobi City county) 2. KEMRI-CRDR Siaya (Siaya county) |
20-04-2020 |
View |
353. |
ECCT/19/12/01 | BOHEMIA PK400 Mosquitocidal effect and pharmacokinetics of different ivermectin dose regimens in preparation for BOHEMIA cluster randomized controlled trial. |
Principal Investigator(s) 1. Marta Ferreira Maia Site(s) in Kenya Kilifi |
01-04-2020 |
View |
354. |
ECCT/19/11/06 | Optimize LNG EC An Open Label Phase 2 Pharmarcokinetic Study to Evaluate Double - Dose Levonorgestrel Emergency Contraception in Combination withEfavirenz Based Antiretroviral Therapy or Rifampicin Containing Anti - Tuberculosis Therapy. A5375 |
Principal Investigator(s) 1. Lucy Chepkurui Koech Site(s) in Kenya KEMRI/WRP Kericho |
19-03-2020 |
View |
355. |
ECCT/19/11/05 | Point-of-care Urine Monitoring of Adherence (PUMA) Point-of-care Urine Monitoring of Adherence (PUMA): Testing a Real-Time Urine Assay of Tenofovir in PrEP Pilot trial to examine the feasibility, acceptability and impact on longer-term adherence of an intervention using a new urine-based tenofovir adherence assay |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya KEMRI-CCR PHRD (THIKA) PROJECT |
15-04-2020 |
View |
356. |
ECCT/19/11/04 | Second line switch to Dolutegravir (2SD) study Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV-1 Infected Adults from Ritonavir boosted Protease Inhibitors to Dolutegravir: An Open-Label Randomized Controlled Trial |
Principal Investigator(s) 1. Loice Achieng Site(s) in Kenya 1. Kenyatta National Hospital (Nairobi City county) 2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 3. Thika Level 5 Hospital (Kiambu county) 4. Kiambu Level 5 Hospital (Kiambu county) |
23-12-2019 |
View |
357. |
ECCT/19/11/03 | A Pilot BE study for Enalpril 5mg A bioequivalent pilot study of a locally-produced brand of enalapril tablets: a key step towards implementation of bioequivalent study regulatory requirements in East Africa |
Principal Investigator(s) 1. Simon Njoroge Njenga Site(s) in Kenya Kenya Medical Research Institute |
09-04-2020 |
View |
358. |
ECCT/19/11/02 | PrEP and dPEP PrEP and dPEP: Doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections among Kenyan women using HIV pre-exposure prophylaxis |
Principal Investigator(s) 1. Dr.Elizabeth Bukusi Ann Bukusi Site(s) in Kenya KEMRI/CMR/RCTP Kisumu-Lumumba Sub-County Hospital |
31-01-2020 |
View |
359. |
ECCT/19/11/01 | A study to determine if candidate malaria vaccines are safe, effective, and induce immunity among Kenyan adults. Safety, immunogenicity, and efficacy of R21/Matrix M (R21/MM) and ChAd63/MVA-ME-TRAP in the context of controlled human malaria infection: A Phase IIb Trial in Kenyan Adults. |
Principal Investigator(s) 1. Melissa Kapulu Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
07-08-2021 |
View |
360. |
ECCT/19/10/03 | Smoking Cessation Study for PLHIV Optimizing Smoking Cessation Interventions For People Living With Human Immunodeficiency Virus in Nairobi, Kenya |
Principal Investigator(s) 1. Dr. Seth Scott Himelhoch Seth Scott Himelhoch Site(s) in Kenya Mathari National Teaching and Referral Hospital |
03-04-2020 |
View |